On the evening of August 20, United Imaging Healthcare released its 2026 half‑year report. The company posted revenue of RMB 7.052 billion in the first half of the year, representing a 17.22% year‑on‑year increase. Its net profit attributable to parent shareholders stood at RMB 897 million, down 10.
On August 12, 2026, tricuspid‑valve interventional device developer Versa Vascular announced two major adjustments.
On August 10, Teledyne Technologies and Varex Imaging (hereinafter‑referred to as "Varex") jointly announced the signing of a definitive acquisition agreement.
Philips has recently partnered with six companies to expand its capabilities in wearable devices and out‑of‑hospital patient monitoring.
On August 3, 2026, Andromeda Surgical, a developer of autonomous surgical robots for urology, announced the completion of its US$15‑million Series‑A financing round.
On August 3, Shanghai Zhudong Technology Co., Ltd. announced the completion of its angel round financing, led by CAS Star. Co-investors include Legend Star, Ventech China, Daotong Investment, Inno Angel Fund, BGI Songhe Life Science Fund, Jifeng Capital and Jiadao Capital.
On July 28, 2026, Dutch regenerative medicine firm Xeltis announced the completion of its latest financing round, raising USD 23.3 million (EUR 20.5 m
On July 23, 2026, Suzhou Sightways Medical Technology Co., Ltd. (referred to as Sightways Robotics) officially announced the completion of its Series A+ financing round, led by Chuanggu Capital.
Stryker Corporation announced today that it has completed the acquisition of Amplitude Vascular Systems (AVS). The transaction amount was not disclosed .
Diagens' reach now extends to over 400 medical institutions across China, including adoption by 40% of the nation's top ten hospitals.
Should the transaction complete, J&J will inherit Atraverse's radiofrequency system for simplifying access to the heart's left atrium.
The company, whose shares climbed nearly 8% Wednesday morning, also said a recent cyber incident has been contained and did not significantly affect first-quarter results.
The medical device giant acquired an AI-powered coronary assessment company for $585M and led a $100M strategic round for a pulmonary hypertension therapy pioneer.
Accelerating Clinical Milestones: Multi-Center Trials for BMI Systems Set for Mid-2026, Neuromodulation Pipeline Advances
